{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T04:31:15Z","timestamp":1772598675144,"version":"3.50.1"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"2","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,6]]},"abstract":"<jats:title>Summary:<\/jats:title>\n                  <jats:p>In this issue of Cancer Discovery, Chen and colleagues demonstrate that, in preclinical models, HER2 expression level directly affects trastuzumab deruxtecan internalization and cytotoxicity, with clinical data revealing divergent target dynamics depending on whether HER2 functions as an oncogenic driver or a dispensable antigen. Together with prior preclinical and clinical evidence, these findings support a context-dependent model in which target downregulation predominates in HER2-low disease, whereas payload resistance or rare binding-site mutations may dominate resistance in HER2-addicted tumors, with important implications for antibody\u2013drug conjugate selection and sequencing.<\/jats:p>\n                  <jats:p>See related article by Chen et al., p. 235<\/jats:p>","DOI":"10.1158\/2159-8290.cd-25-2102","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T08:11:23Z","timestamp":1770365483000},"page":"195-197","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Different Diseases, Different Escapes: Trastuzumab Deruxtecan Resistance in HER2-Amplified versus HER2-Low Breast Cancer"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-2842","authenticated-orcid":false,"given":"Tess A.","family":"O\u2019Meara","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts."},{"name":"3Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-0228","authenticated-orcid":false,"given":"Paolo","family":"Tarantino","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts."},{"name":"3Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"2026020910345453900_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"2026020910345453900_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/2159-8290.CD-25-0647","article-title":"Trastuzumab deruxtecan (T-DXd) resistance via loss of HER2 expression and binding","volume":"16","author":"Chen","year":"2026","journal-title":"Cancer Discov"},{"key":"2026020910345453900_bib3","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"key":"2026020910345453900_bib4","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov"},{"key":"2026020910345453900_bib5","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"key":"2026020910345453900_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026020910345453900_bib7","doi-asserted-by":"crossref","first-page":"e431766","DOI":"10.1200\/EDBK_431766","article-title":"Unlocking the potential: biomarkers of response to antibody-drug conjugates","volume":"44","author":"Ascione","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026020910345453900_bib8","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"2026020910345453900_bib9","doi-asserted-by":"crossref","first-page":"104894","DOI":"10.1016\/j.esmoop.2025.104894","article-title":"322P Human epidermal growth factor receptor 2 (HER2)-directed therapies administered after trastuzumab deruxtecan (T-DXd) remain effective in patients (pts) with metastatic breast cancer (mBC): exploratory analysis from DESTINY-Breast02 and -03","volume":"10","author":"Fasching","year":"2025","journal-title":"ESMO Open"},{"key":"2026020910345453900_bib10","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2\u2212 and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/2\/195\/3731663\/cd-25-2102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/2\/195\/3731663\/cd-25-2102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:34:57Z","timestamp":1770651297000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/2\/195\/772112\/Different-Diseases-Different-Escapes-Trastuzumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,6]]},"published-print":{"date-parts":[[2026,2,6]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-25-2102","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]}}}